A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Exclusion Criteria

• •Previous use of approved anti-VEGF or Avastin® within 4 weeks preceding randomization
• •Macular edema due to something other than exudative AMD, DME or BRVO, in the study eye
• •History of inadequate response to previous intravitreal anti-VEGF therapy
• •History of any intraocular or periocular corticosteroid injection or implant, in the study eye
• •Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization
• •Any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss during the study period
• •Active intraocular inflammation in the study eye
• •Current vitreous hemorrhage in the study eye
• •Polypoidal choroidal vasculopathy (PCV) in the study eye
• •History of idiopathic, infectious or autoimmune-associated uveitis in either eye
• •Current ocular or periocular infection, such as conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
• •Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)
• •Premenopausal women not using adequate contraception
• •Current treatment for active systemic infection
• •Known allergy to any component of the study drug , not amenable to treatment